24 Amino Acid Residues In Defined Sequence Patents (Class 530/325)
-
Publication number: 20120190611Abstract: The present disclosure provides a method, composition and kit for treatment of inflammatory disease and disorder using PKC isoform modulators. Exemplary modulators include inhibitors of PKC-alpha, PKC-epsilon and PKC-eta, as well as activators of PKC-delta.Type: ApplicationFiled: July 13, 2011Publication date: July 26, 2012Inventors: Liora Braiman-Wiksman, Tamar Tennenbaum, Yuvai Sagiv, Marina Gartsbein, Ephraim Brener, Moshe Ben-Hamo, Liat Hammer
-
Publication number: 20120190626Abstract: The present invention provides a peptide which functions as a mimic peptide of an amyloid ? peptide and is capable of inhibiting the fibrillogenesis of an amyloid ? peptide. The present invention relates to an 8- to 30-amino acid residue peptide comprising an amino acid sequence represented by the following formula (I): X1-Asp-X2-X3-X4-Pro-X5-X6 (SEQ ID NO: 28) (I), wherein X1 represents a branched chain amino acid, and X2, X3, X4, X5, and X6 are the same or different and each represents an ?-amino acid, and to a pharmaceutical composition and an amyloid ? fibrillogenesis inhibitor comprising the peptide.Type: ApplicationFiled: December 16, 2011Publication date: July 26, 2012Inventor: Kazuhisa SUGIMURA
-
Publication number: 20120184710Abstract: The present invention relates to an isolated nucleic acid molecule encoding a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a vector comprising such nucleic acid molecule, a host cell comprising such vector, a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a process for producing such protein, a process for producing a cell which expresses such protein, an antibody that binds to such protein, a hybridoma cell producing such antibody, a method for producing such antibody, a pharmaceutical composition comprising such nucleic acid molecule, protein, or antibody, use of such nucleic acid molecule, protein, or antibody for the manufacture of a medicament, a method for identifying an antagonist capable of reducing or inhibiting the activity of such protein, a method for diagnosis or treatment of an infection with a pathogen causing Lyme disease or an infection with Borrelia burgdorferi s.l.Type: ApplicationFiled: March 2, 2012Publication date: July 19, 2012Applicant: INTERCELL AGInventors: URBAN LUNDBERG, ANDREAS MEINKE, ESZTER NAGY, ALEXANDER VON GABAIN, BIRGIT NOIGES, DIETER GELBMANN, ALBINA POLJAK, CHRISTINE TRISKA
-
Publication number: 20120183979Abstract: Disclosed are cloning and expression of a plurality of protein fragments of virB10, a Type IV Secretion System (TIVSS) in Anaplasma phagocytophilum. Such recombinant protein fragments are useful in the ELISA detection of anaplasma pathogen. The use of same as kits for ELISA is also disclosed.Type: ApplicationFiled: March 13, 2012Publication date: July 19, 2012Applicant: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.Inventors: John G. Hoey, Denise P. Dimitrov, Lisa P. Huang, Martin E. Adelson, Eli Mordechai
-
Patent number: 8222211Abstract: A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a TH2 type cytokine bias. In addition PIF peptides enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators, therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection.Type: GrantFiled: October 22, 2004Date of Patent: July 17, 2012Assignee: BioIncept, LLCInventor: Eytan R. Barnea
-
Publication number: 20120177669Abstract: We characterized a total of 175 HLA-DR-associated phosphopeptides using sequential affinity isolation, biochemical enrichment, mass spectrometric sequencing and comparative analysis. Many were derived from source proteins which may have roles in cancer development, growth and metastasis. Most were expressed exclusively by either melanomas or transformed B cells, suggesting the potential to define cell type-specific phosphatome “fingerprints”. We generated HLA-DR?1*0101-restricted CD4+ T cells specific for a phospho-MART-1 peptide identified in two melanoma cell lines. These T cells showed specificity for phosphopeptide-pulsed antigen presenting cells as well as for intact melanoma cells. MHC II-restricted phosphopeptides recognizable by human CD4+ T cells are potential targets for cancer immunotherapy.Type: ApplicationFiled: May 4, 2010Publication date: July 12, 2012Applicants: UNIVERSITY OF VIRGINIA PATENT FOUNDATION, THE JOHNS HOPKINS UNIVERSITYInventors: Suzanne L. Topalian, Florence Depontieu, Donald Hunt, Jeffrey Shabanowitz, Jie Qian, Victor Engelhard, Angela Zaring
-
Publication number: 20120178102Abstract: The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S1, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S1, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.Type: ApplicationFiled: January 9, 2012Publication date: July 12, 2012Applicant: Antigenics Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Publication number: 20120178700Abstract: The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.Type: ApplicationFiled: September 22, 2009Publication date: July 12, 2012Applicant: Aileron Therapeutics, Inc.Inventors: Huw M. Nash, Rosana Kapeller-Libermann, Jiawen Han, Tomi K. Sawyer, Justin Noehre
-
Patent number: 8217142Abstract: The invention relates to improved liquid phase processes for the preparation of the 21 residue protein component, (Lys-Leu4)4-Lys, of the pulmonary surfactant KL-4. These process are amenable to large scale synthesis and one process employs a method of saponifying an ester which reduces the inherent racemization of the ?-carbon.Type: GrantFiled: September 30, 2008Date of Patent: July 10, 2012Assignee: Ortho Pharmaceutical CorporationInventors: Ahmed F. Abdel-Magid, Urs Eggmann, Cynthia Anne Maryanoff, Adrian Thaler, Frank J. Villani
-
Publication number: 20120172285Abstract: A series of stapled BCL-2 family peptide helices were identified as able to target the survival protein MCL-I with high affinity and a subset with unprecedented selectivity. Agents and methods for selective pharmacologic neutralization of MCL-I are provided for drug discovery and therapeutic uses, including use in overcoming the apoptotic resistance of cancer and other diseases associated with impaired cell death.Type: ApplicationFiled: December 9, 2009Publication date: July 5, 2012Inventors: Loren D. Walensky, Michelle L. Stewart
-
Publication number: 20120164229Abstract: The present invention provides long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer. In particular, the present invention provides a long acting pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.Type: ApplicationFiled: February 29, 2012Publication date: June 28, 2012Applicant: MAPI PHARMA LTD.Inventors: Ehud MAROM, Shai RUBNOV
-
Publication number: 20120164166Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.Type: ApplicationFiled: January 26, 2012Publication date: June 28, 2012Applicants: NOVARTIS AG, J. CRAIG VENTER INSTITUTE, INC.Inventors: Claire Fraser, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
-
Patent number: 8207128Abstract: Described is a polypeptide inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, a fusion protein thereof, a polynucleotide encoding the polypeptide, a vector including the polynucleotide, and a transformant transformed with the vector. Described is also a pharmaceutical composition for the prevention or treatment of inflammatory diseases, or the inhibition of the growth and/or metastasis of cancer cells including the polypeptide or a fusion protein thereof.Type: GrantFiled: September 20, 2006Date of Patent: June 26, 2012Assignee: Supadelixir Inc.Inventors: Jang-Hee Hahn, Kyoung-Jin Lee, Dong-Min Kang
-
Publication number: 20120157389Abstract: The present invention relates to peptide from 4 to 50 amino acids comprising a phosphorylated pYX1X2X1 motif (SEQ ID NO: 1), wherein each X1 independently is M or Nle and X2 is any amino acid, pharmaceutical compositions comprising said peptide and use thereof for treating cancer.Type: ApplicationFiled: December 21, 2010Publication date: June 21, 2012Applicant: GENE SIGNAL INTERNATIONAL SAInventors: Salman Al-Mahmood, Sylvie Colin
-
Publication number: 20120156235Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.Type: ApplicationFiled: December 23, 2009Publication date: June 21, 2012Applicant: MEDIMMUNE, LLC.Inventors: Josephine McAuliffe, Frances Palmer-Hill, Qing Zhu, Joann Suzich
-
Publication number: 20120157659Abstract: This invention describes a process for separating a fusion protein or polypeptide in the form of its precursor from a mixture containing said fusion protein and impurities, which comprises contacting said fusion protein with a resin containing immobilized metal ions, said fusion protein covalently operably linked directly or indirectly to an immobilized metal ion-affinity peptide, binding said fusion protein to said resin, and selectively eluting said fusion protein from said resin.Type: ApplicationFiled: July 23, 2010Publication date: June 21, 2012Applicant: SIGMA-ALDRICH CO.Inventors: Ronald A. Hernan, Richard J. Mehigh, Ian R. Brockie, Elizabeth Jenkins
-
Patent number: 8202841Abstract: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.Type: GrantFiled: June 17, 2005Date of Patent: June 19, 2012Assignee: MannKind CorporationInventors: Liping Liu, Zhidong Xie, David C. Diamond
-
Publication number: 20120149640Abstract: The invention relates to peptides for modulate IGF-1 activity, a pharmaceutical composition comprising them as well as their applications as medicinal products and cell proliferation modulating agents in vitro.Type: ApplicationFiled: March 18, 2010Publication date: June 14, 2012Inventors: Claude Carelli, Zvi Laron, Gila Maor
-
Publication number: 20120142892Abstract: According to the present invention, there is provided a range of new conotoxin derivatives and methods for synthesizing these analogues and other intramolecular dicarba bridge-containing peptides, including dicarba-disulfide bridge-containing peptides.Type: ApplicationFiled: February 16, 2012Publication date: June 7, 2012Applicants: POLYCHIP PHARMACEUTICALS PTY LTD., MONASH UNIVERSITYInventors: Andrea Robinson, Jomana Elaridi
-
Patent number: 8193311Abstract: An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain capable of specifically binding a CD44 polypeptide as set forth in SEQ ID NO: 2 and incapable of binding a CD44 polypeptide selected from the group consisting of: SEQ ID NO: 4 or 6.Type: GrantFiled: February 7, 2011Date of Patent: June 5, 2012Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: David Naor, Shlomo Nedvetzki, Itshak Golan, Irina Kessel, Lora Melnik
-
Publication number: 20120134931Abstract: Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A-X-B-C)-M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and M is a macromolecular carrier.Type: ApplicationFiled: July 15, 2010Publication date: May 31, 2012Applicant: REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Roger Tsien, Tood Aguilera, Emilia Olson, Tao Jiang, Quyen Nguyen
-
Publication number: 20120135024Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.Type: ApplicationFiled: March 23, 2011Publication date: May 31, 2012Applicants: NOVARTIS AG, J. CRAIG VENTER INSTITUTE, INC.Inventors: Claire FRASER, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
-
Publication number: 20120129776Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.Type: ApplicationFiled: September 18, 2007Publication date: May 24, 2012Inventors: Yossi Cohen, Ronen Shemesh, Amir Toporik, Zurit Levine, Assaf Wool, Dvir Dahary, Iris Hecht, Merav Beiman, Galit Rotman, Michal Ayalon-Soffer
-
Publication number: 20120129264Abstract: The present invention relates to peptides, nucleic acids and methods for transforming a bacterium belonging to the Streptococcus genus by natural competence and their use in the food and feed industry.Type: ApplicationFiled: June 23, 2010Publication date: May 24, 2012Applicant: DANISCO A/SInventors: Patrick Boyaval, Christophe Fremaux, Pascal Hols, Laetitia Fontaine, Philippe Horvath
-
Publication number: 20120129771Abstract: The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided.Type: ApplicationFiled: February 1, 2012Publication date: May 24, 2012Applicant: AMGEN INC.Inventors: Thomas C. Boone, Kenneth C. Wild, Karen C. Sitney, Hosung Min, Bruce Kimmel
-
Publication number: 20120128704Abstract: The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin.Type: ApplicationFiled: February 9, 2010Publication date: May 24, 2012Applicants: Max-Delbrueck-Centrum fuer Molekulare Medizin, HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZEN TRUM FUER GESUNDHEIT UND UMWELT (GMBH)Inventors: Dolores J. Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Publication number: 20120121591Abstract: Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a half-life extending moiety. Also disclosed are a method of preventing or mitigating a relapse of a symptom of multiple sclerosis and a method of treating an autoimmune disorder using the compositions.Type: ApplicationFiled: March 19, 2010Publication date: May 17, 2012Applicant: Amgen Inc.Inventors: John K. Sullivan, Leslie P. Miranda, Colin V. Gegg, Shaw-Fen Sylvia Hu, Edward J. Belouski, Justin K. Murray, Hung Nguyen, Kenneth W. Walker, Taruna Arora, Frederick W. Jacobsen, Yue-Sheng Li, Thomas C. Boone
-
Publication number: 20120121601Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.Type: ApplicationFiled: January 13, 2012Publication date: May 17, 2012Applicant: Schering CorporationInventors: Madaline Chirica, Robert A. Kastelein, Kevin W. Moore, Christi L. Parham
-
Publication number: 20120121623Abstract: The present invention relates to monomeric and multimeric peptidic compounds which have antipathogenic, in particular antiviral or/and antibacterial activity. In a preferred aspect, the peptide compounds of the invention have an activity in respect of a broad spectrum of viruses, both DNA and RNA viruses, irrespective of whether they possess virus envelope or not. Further, the present invention refers to compositions comprising said peptidic compounds for medical use, i.e. for the treatment or prevention of pathogenic, in particular viral or/and bacterial infections.Type: ApplicationFiled: August 5, 2010Publication date: May 17, 2012Applicant: SPIDERBIOTCH S.r.L.Inventors: Andrea Giuliani, Giovanna Pirri, Lorena Pizzuto, Santo Landolfo, Giorgio Gribaudo, David Lembo, Davide Gibellini
-
Publication number: 20120121590Abstract: The invention provides Galectin-3 binding protein (Gal-3BP, BTBD17B) polypeptide sequences and compositions that include Gal-3BP polypeptide sequences, and methods of using Gal-3BP polypeptide sequences, including modified forms and wild type (native) forms of Gal-3BP polypeptide, such as in treatment, diagnostic, detection and prognostic methods.Type: ApplicationFiled: April 16, 2010Publication date: May 17, 2012Inventors: Klaus Ley, Christian Gleissner
-
Publication number: 20120122788Abstract: The present invention relates to ?-polylysine conjugates, in particular conjugates of ?-polylysine with compounds carrying carboxyl groups, and to the preparation and use thereof for targeting of the kidney.Type: ApplicationFiled: July 9, 2010Publication date: May 17, 2012Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNGInventors: Armin Kuebelbeck, Gregor Larbig, Walter Mier, Barbro Beijer, Uwe Haberkorn
-
Patent number: 8178107Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.Type: GrantFiled: April 18, 1995Date of Patent: May 15, 2012Assignee: Genentech, Inc.Inventors: Dan L. Eaton, Frederic J. De Sauvage
-
Publication number: 20120115789Abstract: The present invention relates to compounds which inhibit or antagonize the binding of methylglyoxal (MG) and/or other reactive carbonyl species (RCS) to an arginine- or lysine- containing protein, preferably an arginine- or lysine-containing cellular protein, such as a sodium ion channel, e.g. the sodium ion channel Na(v)1.8. Preferred scavenger compounds are peptides comprising several or multiple repeats of the amino acid sequence motif Gly-Glu-X-Pro (GEXP), wherein X is Arg or Lys, and pharmaceutical compositions thereof. The present invention furthermore relates to the use of the compounds as scavenger or antagonists of methylglyoxal and/or related reactive carbonyl species (RCS). The present invention furthermore relates to the use of the compounds for the prevention and/or treatment of pain, hyperalgesia and pain related diseases, in particular pain and/or hyperalgesia caused by or associated with methylglyoxal and/or reactive carbonyl species (RCS).Type: ApplicationFiled: May 26, 2010Publication date: May 10, 2012Inventors: Peter Nawroth, Angelika Bierhaus, Thomas Fleming
-
Publication number: 20120115164Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.Type: ApplicationFiled: December 20, 2011Publication date: May 10, 2012Applicant: Schering CorporationInventors: Jacqueline C. Timans, Stefan Karl-Heinz Pflanz, Robert A. Kastelein, J. Fernando Bazan, Donna Rennick, Rene de Waal Malefyt, Jeanne Cheung
-
Publication number: 20120114679Abstract: The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors in humans, using compounds based on small peptides. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier.Type: ApplicationFiled: November 28, 2011Publication date: May 10, 2012Applicant: Nymox Pharmaceutical CorporationInventors: Paul Averback, Jack Gemmell
-
Publication number: 20120115162Abstract: Antibodies that specifically bind to fatty acid amide hydrolases and methods of using the antibodies are provided herein.Type: ApplicationFiled: April 22, 2010Publication date: May 10, 2012Applicant: INFINITY PHARMACEUTICALS, INC.Inventors: Janid A. Ali, James Brownell, Erin Brophy, Thomas T. Tibbitts
-
Publication number: 20120107243Abstract: The peptides described herein can function as carrier peptides. These peptides can associate with (e.g., non-covalently bind) biologically active molecules or imaging agents to transport the biologically active molecules or imaging across the blood-brain barrier. In some cases, such transport may increase the effectiveness of the biological molecules or imaging agents.Type: ApplicationFiled: July 14, 2010Publication date: May 3, 2012Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Geoffry L. Curran, Gobinda Sarkar, Joseph F. Poduslo, Robert B. Jenkins, Val J. Lowe, Eric W. Mahlum
-
Publication number: 20120100172Abstract: The present invention relates to immunogenic peptides, including variants and analogs derived from Streptococcus pneumoniae (S. pneumoniae) proteins, to peptide-multimers, conjugates and fusion proteins that include such peptides, and to vaccines that include such immunogenic entities. In particular, the present invention relates to the use of such vaccines for eliciting protective immunity to S. pneumoniae.Type: ApplicationFiled: June 3, 2010Publication date: April 26, 2012Inventors: Michael Tal, Maxim Portnoi, Ron Dagan, Yaffa Mizrachi-Nebenzahl
-
Publication number: 20120093846Abstract: Fusion protein for immunocastration (Sequences 1a and 1b) that comprises the primary amino acid sequence of the gonadotrophin-liberating protein fused to a theoretical sequence: NH2-QHWSYGLRPGGPPFSGGGGPPFSA-COOH??Sequence 1a NH2-GPPFSGGGGPPFSAQHWSYGLRPG-COOH;??Sequence 1b DNA sequences coding for said fusion protein; vaccine comprising said fusion protein; use of the fusion protein for mammal immunocastration; process for producing the vaccine; process for preparing the fusion protein that comprises fusing the amino acid sequence of the gonadotrophin-liberating hormone (GnRH-I) to a theoretical glycosilable sequence having immunogenic activity that does not include pathogen or “carrier” protein sequences in its structure.Type: ApplicationFiled: April 14, 2010Publication date: April 19, 2012Inventor: Leonardo Enrique Saenziturriaga
-
Publication number: 20120094924Abstract: Polymers including two or more different recurring units are disclosed herein. Also disclosed herein are methods of using such polymers to deliver nucleic acids to a cell.Type: ApplicationFiled: October 13, 2011Publication date: April 19, 2012Applicant: Nitto Denko CorporationInventors: Padmanabh Chivukula, Jian Liu, Akinobu Soma, Keisaku Okada, Sang Van, Chen-Chang Lee, Lei Yu
-
Publication number: 20120093851Abstract: The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT1 53, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.Type: ApplicationFiled: March 8, 2010Publication date: April 19, 2012Inventors: Guido Grandi, Oretta Finco, Renata Maria Grifantini
-
Publication number: 20120088722Abstract: The present invention provides compounds for disrupting the binding of a matrix metalloprotease (MMP) protein to a substrate protein at an interaction site other than the protease catalytic site. In particular the inventive compounds inhibit the MMP's ability to cleave a substrate protein. In some cases the compound may prevent activation of transforming growth factor beta (TGF?). The compounds are preferably polypeptide fragments of the hemopexin-like domain of the MMP, but may be mimetics thereof or peptides or mimetics of the portion of the MMP substrate protein to which the MMP interacts.Type: ApplicationFiled: October 7, 2011Publication date: April 12, 2012Inventors: Marina D'Angelo, Abdulhafez Selim
-
Publication number: 20120088902Abstract: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders and disorders and conditions associated with excess fluid and/or salt retention as well as other conditions and disorders are described. The compositions feature polypeptides that activate the guanylate cyclase C (GC-C) receptor.Type: ApplicationFiled: June 27, 2007Publication date: April 12, 2012Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: Mark G. Currie, Daniel P. Zimmer
-
Publication number: 20120083585Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.Type: ApplicationFiled: October 25, 2011Publication date: April 5, 2012Inventors: Richard KINNEY, Claire Y.H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
-
Publication number: 20120083584Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.Type: ApplicationFiled: October 25, 2011Publication date: April 5, 2012Inventors: Richard KINNEY, Claire Y.H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
-
Patent number: 8143374Abstract: The present invention is related to novel parathyroid hormone polypeptide derivatives, and to pharmaceutical composition containing the polypeptides, as well as synthetic and recombinant methods for producing the polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing the polypeptides of the present invention. The present invention further provides diagnostic and therapeutic methods using the polypeptide derivatives.Type: GrantFiled: August 3, 2007Date of Patent: March 27, 2012Assignee: The General Hospital CorporationInventors: Henry M. Kronenberg, John T. Potts, Jr., Thomas J. Gardella
-
Patent number: 8142764Abstract: The present invention provides streptococcal SspB Adherence Region (BAR) peptides consisting of Formula I: R18-R1- R2-Val-R3-R4-Leu-Leu-R5-R6-R7-Ile-R8-R9-Lys-R10-R19 , wherein R2, is 1-3 Lys residues; R3 is any amino acid residue except a Pro residue; R4 is any amino acid residue except a Pro residue; R5 is 1-3 Lys residues; R6 is 1-10 amino acid residues; R7 is any amino acid residue except Asp, Glu, Gly or Pro; R8 is any amino acid residue except Ala, Asp, Gly, His, Ile, Pro, Trp or Tyr; R9 is a Val, Ile, Phe, or Trp residue; R10 is 0-1 Cys residue; R18 is 0 amino acids or R12-R11-Pro-, wherein R11 is 0-3 amino acids, wherein the amino acid residues are not Gly or Pro; and R12 is 0-1 Cys residues; and R19 is R13-R14-R15-R16-R17, wherein R13 is 0-1 is Gly residue; R14 is 0-1 Ala residue; R15 is 0-1 Phe residue; R16 is 0-1 Gln residue; R17 is 0-1 Cys residue; and wherein R1 is an ornithine residue; or wherein both R1 and R10 are both Cys and R1 and R10 are covalently linked to form a circular peptide; or wheType: GrantFiled: February 25, 2009Date of Patent: March 27, 2012Assignee: University of Louisville Research FoundationInventors: Donald R. Demuth, Carlo Amorin Daep
-
Publication number: 20120070493Abstract: Provided herein are compositions and methods related to MHC II binding peptides. In some embodiments, the peptides are obtained or derived from a common source. In other embodiment, the peptides are obtained or derived from an infectious agent to which a subject has been repeatedly exposed.Type: ApplicationFiled: August 23, 2011Publication date: March 22, 2012Applicant: Selecta Biosciences, Inc.Inventors: CHRISTOPHER FRASER, Grayson B. Lipford, David H. Altreuter
-
Publication number: 20120070875Abstract: The present invention provides peptide conjugates having improved solubility as well as increased secretion during cell based production, as well as methods of utilizing such peptides. The peptide conjugates include a short peptide domain defined by the amino acid sequence AGIH (SEQ ID NO: 8) and may include a biologically active molecule useful in intracellular and intranuclear transport of the biologically active molecule to treat various disorders and diseases.Type: ApplicationFiled: May 27, 2010Publication date: March 22, 2012Inventor: Richard H. Weisbart
-
Publication number: 20120065139Abstract: Provided are a series of Gq protein competitive inhibitory polypeptides (GCIPs), polynucleotides encoding them, and preparation methods thereof. Also provided are pharmaceutical compositions comprising GCIP polypeptides and their uses in the manufacture of drugs for treating myocardial hypertrophy.Type: ApplicationFiled: August 11, 2008Publication date: March 15, 2012Inventors: Xiaohui LI, Haigang Zhang, Jianzhi Zhou, Shuhui Li